Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionSTF Management LP
Latest Disclosed Ownership527 shares
Latest Disclosed Value $ 406,775
STF Management LP reports 51.34% decrease in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On February 5, 2026 - STF Management LP filed a 13F-HR form disclosing ownership of 527 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $406,775 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 12, 2025 disclosing 1,083 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of -51.34% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-05 2025-12-31 13F Regeneron Pharmaceuticals COM 75886F107 527 -556 -51.34 407 -33.22 0.3818
2025-11-12 2025-09-30 13F Regeneron Pharmaceuticals COM 75886F107 1,083 -6 -0.55 609 6.48 0.2258
2025-08-07 2025-06-30 13F Regeneron Pharmaceuticals COM 75886F107 1,089 42 4.01 572 -14.01 0.2256
2025-05-13 2025-03-31 13F Regeneron Pharmaceuticals COM 75886F107 1,047 79 8.16 664 -3.63 0.3188
2025-02-12 2024-12-31 13F Regeneron Pharmaceuticals COM 75886F107 968 -589 -37.83 690 -57.89 0.3094
2024-11-12 2024-09-30 13F Regeneron Pharmaceuticals COM 75886F107 1,557 -157 -9.16 1,637 -9.16 0.7447
2024-08-09 2024-06-30 13F Regeneron Pharmaceuticals COM 75886F107 1,714 -75 -4.19 1,801 4.65 0.7596
2024-05-01 2024-03-31 13F Regeneron Pharmaceuticals COM 75886F107 1,789 -37 -2.03 1,722 7.36 0.7470
2024-02-09 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,826 72 4.10 1,604 11.09 0.7538
2023-11-03 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,754 1,077 159.08 1,443 196.91 0.7663
2023-08-02 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 677 -544 -44.55 486 -51.55 0.5239
2023-05-12 2023-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,221 506 70.77 1,003 94.76 0.6761
2023-02-14 2022-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 715 715 516 0.7408
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.